155 related articles for article (PubMed ID: 7863794)
1. Suppression of hepatic natural killer activity by liver metastasis of cancer and restoration of killer activity by oral administration of a Basidomycetes-derived polysaccharide, PSK.
Suo J; Tanaka N; Hizuta A; Yunoki S; Orita K
Acta Med Okayama; 1994 Oct; 48(5):237-42. PubMed ID: 7863794
[TBL] [Abstract][Full Text] [Related]
2. An in vivo study of hepatic and splenic interleukin-1 beta mRNA expression following oral PSK or LEM administration.
Morinaga H; Tazawa K; Tagoh H; Muraguchi A; Fujimaki M
Jpn J Cancer Res; 1994 Dec; 85(12):1298-303. PubMed ID: 7852192
[TBL] [Abstract][Full Text] [Related]
3. Activation of human natural killer cells by the protein-bound polysaccharide PSK independently of interferon and interleukin 2.
Kariya Y; Inoue N; Kihara T; Okamoto N; Sugie K; Mori T; Uchida A
Immunol Lett; 1992 Feb; 31(3):241-5. PubMed ID: 1372283
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of antitumor cytotoxicity of hepatic lymphocytes by oral administration of PSK.
Yunoki S; Tanaka N; Hizuta A; Orita K
Int J Immunopharmacol; 1994 Feb; 16(2):123-30. PubMed ID: 8181901
[TBL] [Abstract][Full Text] [Related]
5. Neonatal inoculation with the protein-bound polysaccharide PSK increases resistance of adult animals to challenge with syngeneic tumor cells and reduces azoxymethane-induced precancerous lesions in the colon.
Matsunaga K; Iijima H; Kobayashi H
Cancer Epidemiol Biomarkers Prev; 2000 Dec; 9(12):1313-22. PubMed ID: 11142416
[TBL] [Abstract][Full Text] [Related]
6. Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells.
Lu H; Yang Y; Gad E; Wenner CA; Chang A; Larson ER; Dang Y; Martzen M; Standish LJ; Disis ML
Clin Cancer Res; 2011 Jan; 17(1):67-76. PubMed ID: 21068144
[TBL] [Abstract][Full Text] [Related]
7. Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview.
Kobayashi H; Matsunaga K; Oguchi Y
Cancer Epidemiol Biomarkers Prev; 1995; 4(3):275-81. PubMed ID: 7606203
[TBL] [Abstract][Full Text] [Related]
8. [Restoration of immunologic responsiveness by PSK in tumor-bearing animals].
Matsunaga K; Morita I; Oguchi Y; Fujii T; Yoshikumi C; Nomoto K
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3468-75. PubMed ID: 3789758
[TBL] [Abstract][Full Text] [Related]
9. [Competitive effect of PSK against the immunosuppressive effect induced in the sera of mice bearing syngeneic tumors].
Matsunaga K; Morita I; Oguchi Y; Fujii T; Yoshikumi C; Nomoto K
Gan To Kagaku Ryoho; 1986 Dec; 13(12):3461-7. PubMed ID: 3789757
[TBL] [Abstract][Full Text] [Related]
10. Effect of Krestin (PSK) on the induction of IL-2 activated killer cells.
Sakamaki S; Kohgo Y; Nojiri S; Kanisawa Y; Ito Y; Takahashi M; Ueno Y; Hirayama Y; Niitsu Y
Jpn J Clin Oncol; 1992 Apr; 22(2):79-83. PubMed ID: 1619782
[TBL] [Abstract][Full Text] [Related]
11. Protein bound polysaccharide PSK abrogates more efficiently experimental metastases derived from H-2 negative than from H-2 positive fibrosarcoma tumor clones.
Algarra I; Collado A; Garrido F
J Exp Clin Cancer Res; 1997 Dec; 16(4):373-80. PubMed ID: 9505208
[TBL] [Abstract][Full Text] [Related]
12. Effects of biological response modifiers with different modes of action used separately and together on immune responses in mice with syngeneic tumours.
Matsunaga K; Morita I; Iijima H; Endoh H; Oguchi Y; Yoshimura M; Fujii T; Yoshikumi C; Nomoto K
J Int Med Res; 1992 Sep; 20(5):406-21. PubMed ID: 1280606
[TBL] [Abstract][Full Text] [Related]
13. [Effects of pretreatment with lentinan or krestin on antitumor effector cell activities suppressed by cyclophosphamide].
Yang ZB
Hokkaido Igaku Zasshi; 1994 Jan; 69(1):137-45. PubMed ID: 8119654
[TBL] [Abstract][Full Text] [Related]
14. Oral administration of PSK can improve the impaired anti-tumor CD4+ T-cell response in gut-associated lymphoid tissue (GALT) of specific-pathogen-free mice.
Harada M; Matsunaga K; Oguchi Y; Iijima H; Tamada K; Abe K; Takenoyama M; Ito O; Kimura G; Nomoto K
Int J Cancer; 1997 Jan; 70(3):362-72. PubMed ID: 9033641
[TBL] [Abstract][Full Text] [Related]
15. Krestin (PSK).
Tsukagoshi S; Hashimoto Y; Fujii G; Kobayashi H; Nomoto K; Orita K
Cancer Treat Rev; 1984 Jun; 11(2):131-55. PubMed ID: 6238674
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of alpha-galactosylceramide (KRN7000) on spontaneous hepatic metastases requires endogenous interleukin 12 in the liver.
Fuji N; Ueda Y; Fujiwara H; Toh T; Yoshimura T; Yamagishi H
Clin Cancer Res; 2000 Aug; 6(8):3380-7. PubMed ID: 10955826
[TBL] [Abstract][Full Text] [Related]
17. [Antitumor effect of PSK (2): effector mechanism of the antimetastatic effect in the "double grafted tumor system"].
Ebina T; Kohya H
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1847-53. PubMed ID: 3592718
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of mouse liver-associated natural killer activity by biologic response modifiers occurs largely via rapid recruitment of large granular lymphocytes from the bone marrow.
Wiltrout RH; Pilaro AM; Gruys ME; Talmadge JE; Longo DL; Ortaldo JR; Reynolds CW
J Immunol; 1989 Jul; 143(1):372-8. PubMed ID: 2732472
[TBL] [Abstract][Full Text] [Related]
19. Suppression of in vivo tumor-induced angiogenesis by the protein-bound polysaccharide PSK.
Kanoh T; Matsunaga K; Saito K; Fujii T
In Vivo; 1994; 8(2):247-50. PubMed ID: 7522606
[TBL] [Abstract][Full Text] [Related]
20. Competitive action of a biological response modifier, PSK, on a humoral immunosuppressive factor produced in tumor-bearing hosts.
Matsunaga K; Morita I; Iijima H; Endo H; Oguchi Y; Yoshimura M; Fujii T; Yoshikumi C; Nomoto K
J Clin Lab Immunol; 1990 Mar; 31(3):127-36. PubMed ID: 1966997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
